We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Repercussions from the failed Plavix settlement continue at Bristol-Myers Squibb (BMS), with the apparently forced departure of CEO Peter Dolan and Senior Vice President and General Counsel Richard Willard on the recommendation of a federal monitor.
Par Pharmaceutical will be able to launch a version of Unimed Pharmaceuticals' testosterone-replacement product AndroGel more than four years before patent expiration under terms of a settlement announced this week.
Barr Laboratories is raising the stakes in its battle with Actavis to acquire Croatian drugmaker Pliva, announcing it is countering Actavis’ most recent bid.
Teva Pharmaceutical and Endo Pharmaceuticals have settled patent suits launched by Purdue Pharma after they filed to market versions of Purdue’s painkiller OxyContin.
Mylan Laboratories has announced it will acquire a major interest in India-based Matrix Laboratories for $736 million, a deal that will make the company a “global leader” in the generics industry, Mylan’s top executive said.
Congress members and staff have accepted at least $600,000 in travel since 2000, funded by drug and device companies and trade groups, according to a report issued by the Center for Public Integrity (CPI).
While it seems certain Croatian generic drugmaker Pliva will have new owners in the near future, who those owners will be is subject to an escalating bidding war between Barr and Actavis.
Teva Pharmaceutical and Endo Pharmaceuticals have settled patent suits launched by Purdue Pharma after they filed to market versions of Purdue’s painkiller OxyContin.
Mylan Laboratories has announced it will acquire a major interest in India-based Matrix Laboratories for $736 million, a deal that will make the company a “global leader” in the generics industry, Mylan’s top executive said.